2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD

NCT01404208 | Completed Results DMC

• 2 other identifiers: 2011P0008751R01MH093402-01A1
• Study Type: interventional
• Target: 206
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to find out if D-Cycloserine (DCS), taken at the same time as a child gets cognitive behavioral therapy (CBT) can help children with pediatric obsessive-compulsive disorder. Cognitive Behavior Therapy is a talking therapy that will teach children new skills to better cope with his/her OCD. CBT usually uses "exposure-based therapy". This means that the person with OCD slowly learns to deal with things they usually avoid. This is done by moving from less stressful situations to more challenging ones. The investigators hope to enroll about 75 children ages 7-17 years old with OCD in this study at Massachusetts General Hospital (MGH). The National Institute of Mental Health (NIMH) is paying for this study to be done. If your child qualifies for the study, the investigators will assign him or her by chance (like a coin toss) to either the DCS group or the placebo group. You and the study doctor cannot choose your child's study group. Your child will have an equal chance (1 in 2) of being assigned to the DCS group. Your child will be asked to take one or two capsules of the study drug (either DCS or placebo, depending which study group they were assigned to) one hour before CBT visits 4-10. The study coordinator will give your child the study drug at the location of the CBT sessions. This is to make sure that your child takes the study drug one hour before his/her scheduled therapy session. We will ask you to record any bad side effect from the study drug that your child may have before each CBT session. It will take your child about 34 weeks to complete the study. During this time, the investigators will ask you and your child to make a minimum of 17 trips to the study center. There may be up to 23 trips when including CBT Booster sessions. This study uses a placebo. The placebo looks exactly like the DCS, but it contains no DCS. The investigators use placebos in research studies to learn if the the results are caused by the study drug or are due to other reasons. This is a double-blind study. A double-blind study is a study where both the doctor and the study participant do not know whether the study participant is being given DCS or placebo.

Conditions

Obsessive-Compulsive Disorder

Outcome Measures

Primary Outcomes (1)

• Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)

  The CY-BOCS is a measure of severity of OCD symptoms, including interference, time spent on thoughts or behaviors, distress, resistance, etc. The CY-BOCS is measured from 0 to 40, with larger values indicating more severe symptoms. Our outcome measure was the difference between the post treatment and randomization scores. When those values are negative, it indicates a reduction in symptom severity.

  Change from Score at Randomization to Post Treatment

Secondary Outcomes (1)

• Clinical Global Impression-Severity (CGI-Severity)

  Change from Randomization Point to Post Treatment

Study Arms (2)

D-Cycloserine

ACTIVE COMPARATOR

Drug: D-Cycloserine

Sugar Pill

PLACEBO COMPARATOR

Drug: Placebo

Interventions

D-Cycloserine DRUG

25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.

D-Cycloserine

Placebo DRUG

Sugar pill

Sugar Pill

Eligibility Criteria

• Age: 7 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Clinical diagnosis of Obsessive-Compulsive Disorder as primary or co-primary diagnosis
• Score on CY-BOCS of 16 or greater
• Full Scale IQ greater than or equal to 85
• English speaking

You may not qualify if:

• Receiving concurrent psychotherapy or a past adequate trial of CBT for OCD
• Initiation of an antidepressant within 12 weeks before study enrollment
• Initiation of an antipsychotic within 6 weeks before study enrollment
• No new alternative medications, nutritionals, or therapeutic diets within 6 weeks of study enrollment
• Any change in established psychotropic medication within 8 weeks before study enrollment (6 weeks for antipsychotic). Alternative medications must be stable for 6 weeks prior to baseline. Any medications must remain stable during treatment.
• Current clinically significant suicidality
• Suicidal behaviors within six months
• DSM-IV conduct disorder
• DSM-IV autism
• DSM-IV bipolar
• DSM-IV schizophrenia or schizo-affective disorders
• Substance abuse within the past six months
• Hoarding symptoms (due to difficulty implementing E/RP tasks)
• Weight less than 22.5k
• Epilepsy or renal insufficiency

Sponsors & Collaborators

• Massachusetts General Hospital: lead
• National Institute of Mental Health (NIMH): collaborator
• University of South Florida: collaborator

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

Related Publications (1)

• Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M, Geller DA. A preliminary study of D-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry. 2010 Dec 1;68(11):1073-6. doi: 10.1016/j.biopsych.2010.07.015.

  PMID: 20817153 BACKGROUND

Related Links

• The OCD and Related Disorder Program at Massachusetts General Hospital

MeSH Terms

Conditions

Obsessive-Compulsive Disorder

Interventions

Cycloserine

Condition Hierarchy (Ancestors)

Anxiety Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Isoxazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Oxazolidinones; Oxazoles; Serine; Amino Acids, Neutral; Amino Acids; Amino Acids, Peptides, and Proteins

Results Point of Contact

• Title: Dr. Daniel Geller
• Organization: MGH

dan.geller@mgh.harvard.edu

617 724 5141

Study Officials

• Daniel A Geller, M.D.

  Massachusetts General Hospital

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: M.D.

Study Record Dates

• First Submitted: July 25, 2011
• First Posted: July 27, 2011
• Study Start: July 1, 2011
• Primary Completion: September 1, 2015
• Study Completion: December 1, 2016
• Last Updated: March 28, 2017
• Results First Posted: February 27, 2017

Record last verified: 2017-02

Locations

US (1)